Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
暂无分享,去创建一个
M. Fasshauer | M. Stumvoll | M. Blüher | J. Jordan | S. Engeli | N. Klöting | P. Pacher | S. Batkai | M. Schön | J. Berndt
[1] P. Pacher,et al. The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.
[2] M. Maj,et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.
[3] C. Cannon,et al. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. , 2006, Journal of the American College of Cardiology.
[4] J. Klein,et al. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[5] F Xavier Pi-Sunyer,et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.
[6] B. Scatton,et al. The Canadian Consortium for the Investigation of Cannabinoids in Human Therapeutics , 2022 .
[7] D. Cota,et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.
[8] M. Gonthier,et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.
[9] J. Després,et al. Is visceral obesity the cause of the metabolic syndrome? , 2006, Annals of medicine.
[10] J. Després,et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.
[11] Arya M. Sharma,et al. Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.
[12] M. Fasshauer,et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. , 2005, Diabetes.
[13] P. Soubrié,et al. The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] A. Gerber,et al. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH) , 2005, International Journal of Obesity.
[15] K. Mackie,et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.
[16] V. Marzo,et al. Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.
[17] A. Rissanen,et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.
[18] M. Stock,et al. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice , 2005, International Journal of Obesity.
[19] K. Mackie,et al. Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension , 2004, Circulation.
[20] L. Petrocellis,et al. The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.
[21] P. Soubrié,et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.
[22] D. Piomelli. The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.
[23] C. Flachskamm,et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.
[24] A. Finazzi-Agro’,et al. Leptin Activates the Anandamide Hydrolase Promoter in Human T Lymphocytes through STAT3* , 2003, The Journal of Biological Chemistry.
[25] P. Soubrié,et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.
[26] D. Cota,et al. Endogenous cannabinoid system as a modulator of food intake , 2003, International Journal of Obesity.
[27] P. Soubrié,et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.
[28] Lei Wang,et al. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[29] D. Piomelli,et al. A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding , 2002, The Journal of Neuroscience.
[30] P. Widdowson,et al. Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? , 2002, Brain Research.
[31] B. Cravatt,et al. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. , 2002, The Journal of pharmacology and experimental therapeutics.
[32] V. Marzo,et al. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerol , 2002, British journal of pharmacology.
[33] N. Jamshidi,et al. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats , 2001, British journal of pharmacology.
[34] R. Palmiter,et al. Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.
[35] T. Kirkham,et al. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors , 1999, Psychopharmacology.
[36] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[37] J. Widimský,et al. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1998, Diabetes Care.
[38] R. DeFronzo,et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.
[39] M. Storr,et al. Release of anandamide from blood cells , 2006, Clinical chemistry and laboratory medicine.
[40] T. Bisogno,et al. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. , 2005, Molecular human reproduction.
[41] C. Hillard,et al. Modulators of endocannabinoid enzymic hydrolysis and membrane transport. , 2005, Handbook of experimental pharmacology.